Microtubules Inhibitors
3 drugsAbout Microtubules
Microtubules are dynamic cylindrical polymers composed of α- and β-tubulin subunits, essential for cell division, intracellular transport, and cell shape. Disrupting microtubule function can significantly affect cellular processes. This makes them attractive targets, particularly in oncology.
Microtubules have long been recognized as valuable targets for drug development, especially in oncology. Currently, there is no genetic evidence available linking microtubules directly to specific diseases, but the success of existing drugs highlights their therapeutic potential.
Three FDA-approved drugs target microtubules, including DOCIVYX, KLISYRI, and ABRAXANE. All three drugs are small molecules, with applications spanning oncology and other therapeutic areas.
Strategic Insights
ℹ️ How we calculate- Validated target with strong trial activity and 81% attractiveness score.
Top Microtubules Drugs
The competitive landscape includes three companies with approved drugs: ALMIRALL, Bristol-Myers Squibb, and AVYXA HOLDINGS.
The limited number of players suggests relatively low barriers to entry in this space.
Microtubules Drug Modality Landscape
Modalities
Routes of Administration
Microtubules is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
Microtubules Clinical Trials 3,422 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1006 | 487 | 233 | 278 | 68% |
| Phase 2 | 1675 | 658 | 290 | 714 | 69% |
| Phase 3 | 701 | 274 | 73 | 349 | 79% |
| Phase 4 | 40 | 23 | 3 | 14 | 88% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
8 Phase 3 trials testing approved Microtubules drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Microtubules. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Microtubules Drug Approval Timeline (2005 - 2022)
The first microtubule-targeting drug was approved in 2005, with the most recent approval in 2022.
The approval timeline indicates continued interest and potential for further innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 2287 clinical trials targeting Microtubules.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities